Literature DB >> 9432330

Atrophic body gastritis: distinct features associated with Helicobacter pylori infection.

B Annibale1, M Marignani, C Azzoni, G D'Ambra, P Caruana, T D'Adda, G Delle Fave, C Bordi.   

Abstract

BACKGROUND: Usually, atrophic body gastritis has been considered an autoimmune disease characterized by the presence of parietal cell antibodies. Previous investigations into the role of Helicobacter pylori infection have obtained conflicting results. The aim of this study was to investigate the prevalence and role of H. pylori in a prospectively investigated population of patients with corpus-predominant atrophic gastritis. PATIENTS AND METHODS: A consecutive series of 67 newly diagnosed cases of atrophic body gastritis was derived from a screening of 326 patients with unexplained anemia or dyspepsia. Criteria for diagnosis were fasting hypergastrinemia, pentagastrin-resistant achlorhydria, and histological confirmation of body atrophy. In all 67 patients, H. pylori infection was evaluated independently by histological assay and urease test. The gastritis status of both the fundic and antral mucosa were graded according to the Sydney system. Parietal cell and intrinsic factor antibodies also were determined.
RESULTS: Active H. pylori infection was present in 26.8% of our patients and allowed us to identify a patient's subpopulation with a significantly smaller degree of body mucosa damage as shown by functional parameters (gastrin, gastric acid secretion, pepsinogen I) and histological assessment. In this subpopulation, a higher prevalence of gastric cancer familial history was found. Presence of parietal cell antibodies showed a similar prevalence in H. pylori-positive and H. pylori-negative patients (61.1% vs. 69.4%) and was not associated with significant functional and histological differences. Cure of infection determined an evident improvement of corporal atrophy as well as a reduction of hypergastrinemia.
CONCLUSION: Active H. pylori infection, a potential cause of oxyntic gland atrophy, is found in one-fourth of patients with newly diagnosed atrophic body gastritis.

Entities:  

Mesh:

Year:  1997        PMID: 9432330     DOI: 10.1111/j.1523-5378.1997.tb00060.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  19 in total

1.  Supra-angular biopsy is more reliable for atrophy recognization: analysis of 1598 cases for gastric mucosal histological examination.

Authors:  Ya-Li Zhang; Zhuo-Sheng Lai; Dian-Yuan Zhou; Nobutaka Yamada; Min Wen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Artificial neural networks in the recognition of the presence of thyroid disease in patients with atrophic body gastritis.

Authors:  Edith Lahner; Marco Intraligi; Massimo Buscema; Marco Centanni; Lucy Vannella; Enzo Grossi; Bruno Annibale
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

3.  Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection.

Authors:  Yuichi Sato; Mitsuya Iwafuchi; Jun-Ichi Ueki; Akira Yoshimura; Tsutomu Mochizuki; Hirotaka Motoyama; Kazuhito Sugimura; Terasu Honma; Rintaro Narisawa; Takafumi Ichida; Hitoshi Asakura; D H Van Thiel
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

4.  Possible contribution of artificial neural networks and linear discriminant analysis in recognition of patients with suspected atrophic body gastritis.

Authors:  Edith Lahner; Enzo Grossi; Marco Intraligi; Massimo Buscema; Vito-D Corleto; Gianfranco Delle Fave; Bruno Annibale
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

5.  Lack of specific association between gastric autoimmunity hallmarks and clinical presentations of atrophic body gastritis.

Authors:  Bruno Annibale; Edith Lahner; Riccardo Negrini; Flavia Baccini; Cesare Bordi; Bruno Monarca; Gianfranco Delle Fave
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

6.  Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan.

Authors:  Hibiki Ootani; Ryuichi Iwakiri; Ryo Shimoda; Shin Nakahara; Sadahiro Amemori; Takehiro Fujise; Atsushi Kikkawa; Seiji Tsunada; Hiroyuki Sakata; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 7.527

Review 7.  Indications for Helicobacter pylori eradication therapy and first-line therapy regimen in Japan: recommendation by the Japanese Society for Helicobacter Research.

Authors:  Kiichi Satoh
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

8.  The eradication of Helicobacter pylori is affected by body mass index (BMI).

Authors:  Mohamed Abdullahi; Bruno Annibale; Danila Capoccia; Roberto Tari; Edith Lahner; John Osborn; Frida Leonetti; Carola Severi
Journal:  Obes Surg       Date:  2008-04-29       Impact factor: 4.129

9.  Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study.

Authors:  Francesco Cicone; Annalisa Papa; Chiara Lauri; Anna Tofani; Camilla Virili; Marco Centanni; Francesco Scopinaro; Bruno Annibale
Journal:  Endocrine       Date:  2014-09-12       Impact factor: 3.633

10.  Gastric cancer in patients with type I gastric carcinoids.

Authors:  Edith Lahner; Gianluca Esposito; Emanuela Pilozzi; Gloria Galli; Vito D Corleto; Emilio Di Giulio; Bruno Annibale
Journal:  Gastric Cancer       Date:  2014-06-03       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.